In univariate analysis, mOS was significantly longer in NET G3 than in NEC patients (44 months versus 26 months, p = 0.01); however, with the inclusion of the proliferation rate (Ki67) in the multivariate analysis, the difference was no longer statistically significant. The gene discussed is MKI67; the disease is neuroendocrine carcinoma.